The DOI matches its Crossref record; 565 of the 565 references it cites were found in a registry or an index.
2014 Update of the Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception
Open accessAbstract
The Alzheimer's Disease Neuroimaging Initiative (ADNI) is an ongoing, longitudinal, multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer's disease (AD). The initial study, ADNI-1, enrolled 400 subjects with early mild cognitive impairment (MCI), 200 with early AD, and 200 cognitively normal elderly controls. ADNI-1 was extended by a 2-year Grand Opportunities grant in 2009 and by a competitive renewal, ADNI-2, which enrolled an additional 550 participants and will run until 2015. This article reviews all papers published since the inception of the initiative and summarizes the results to the end of 2013. The major accomplishments of ADNI have been as follows: (1) the development of standardized methods for clinical tests, magnetic resonance imaging (MRI), positron emission tomography (PET), and cerebrospinal fluid (CSF) biomarkers in a multicenter setting; (2) elucidation of the patterns and rates of change of imaging and CSF biomarker measurements in control subjects, MCI patients, and AD patients. CSF biomarkers are largely consistent with disease trajectories predicted by β-amyloid cascade (Hardy, J Alzheimer's Dis 2006;9(Suppl 3):151-3) and tau-mediated neurodegeneration hypotheses for AD, whereas brain atrophy and hypometabolism levels show predicted patterns but exhibit differing rates of change depending on region and disease severity; (3) the assessment of alternative methods of diagnostic categorization. Currently, the best classifiers select and combine optimum features from multiple modalities, including MRI, [(18)F]-fluorodeoxyglucose-PET, amyloid PET, CSF biomarkers, and clinical tests; (4) the development of blood biomarkers for AD as potentially noninvasive and low-cost alternatives to CSF biomarkers for AD diagnosis and the assessment of α-syn as an additional biomarker; (5) the development of methods for the early detection of AD. CSF biomarkers, β-amyloid 42 and tau, as well as amyloid PET may reflect the earliest steps in AD pathology in mildly symptomatic or even nonsymptomatic subjects and are leading candidates for the detection of AD in its preclinical stages; (6) the improvement of clinical trial efficiency through the identification of subjects most likely to undergo imminent future clinical decline and the use of more sensitive outcome measures to reduce sample sizes. Multimodal methods incorporating APOE status and longitudinal MRI proved most highly predictive of future decline. Refinements of clinical tests used as outcome measures such as clinical dementia rating-sum of boxes further reduced sample sizes; (7) the pioneering of genome-wide association studies that leverage quantitative imaging and biomarker phenotypes, including longitudinal data, to confirm recently identified loci, CR1, CLU, and PICALM and to identify novel AD risk loci; (8) worldwide impact through the establishment of ADNI-like programs in Japan, Australia, Argentina, Taiwan, China, Korea, Europe, and Italy; (9) understanding the biology and pathobiology of normal aging, MCI, and AD through integration of ADNI biomarker and clinical data to stimulate research that will resolve controversies about competing hypotheses on the etiopathogenesis of AD, thereby advancing efforts to find disease-modifying drugs for AD; and (10) the establishment of infrastructure to allow sharing of all raw and processed data without embargo to interested scientific investigators throughout the world.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SNPs in and around candidate genes including APOE, BIN1, SORL1, and CR1 have been associated with traits including medial temporal lobe atrophy and cortical thickness [225–228]”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [225]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease
Rhinn, H., Fujita, R., Qiang, L., Cheng, R., Lee, J. H., & Abeliovich, A. (2013) · Nature · doi:10.1038/nature12415 · Cited by 151
RetractedMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“Diagnosis of MCI using National Institute on AgingAlzheimer’s Association criteria The NIA-AA criteria for MCI due to AD recently incorporated the use of biomarkers for both amyloid deposition (CSF Ab42, (11)C-PiB-PET) and neuronal injury (CSF tau, hippocampal and whole brain atrophy on MRI, FDG-PET) in addition to cl…”
MethodSelf-citationSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citationImaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347
Self-citationda Luz, A. C. D. D. S., Dias, G. P., Bevilaqua, M. C. D. N., Cocks, G. D., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 4,015
Research works printed but not linked: 14
- Trojanowski J, 2004, Searching for the biomarkers of Alzheimer's, Pract Neurol, 3, 30
- Mueller SG, 2006, Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative, Cogn Dement, 5, 56
- Cruchaga C, 2009, SNPs in the regulatory subunit of calcineurin are associated with CSF tau protein levels, brain mRNA levels, Alzheimers Dement, 5, P471
- LiY WangY WuG ShiF ZhouL LinW et al.Discriminant analysis of longitudinal cortical thickness changes in Alzheimer's disease using dynamic and network features.Neurobiol Aging (in press).
- Thambisetty M, 2012, Effect of Complement CR1 on Brain Amyloid Burden During Aging and Its Modification byAPOEGenotype, Biol Psychiatry, 73, 334
- Weiner MW, 2012, The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception, Alzheimers Dement, 8, S1
- 10.1016/j.bbadis.2011.09.008 · DOI
- 10.1016/j.neuroimage.2009.05.056 · DOI
- 10.3389/fnins.2012.00115 · DOI
- 10.1007/s11682-012-9184-1 · DOI
- 10.1007/s11682-012-9196-x · DOI
- 10.3389/fgene.2011.00073 · DOI
- 10.1016/j.neuroimage.2011.03.077 · DOI
- 10.2174/156720512802455331 · DOI
Cited by
Sorted by citations
Rathore, S., Habes, M., Iftikhar, M. A., Shacklett, A., & Davatzikos, C. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.03.057 · Cited by 622
Dejanovic, B., Huntley, M. A., De Mazière, A., Meilandt, W. J., Wu, T., Srinivasan, K., Jiang, Z., Gandham, V., Friedman, B. A., Ngu, H., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.10.014 · Cited by 517
Weiner, M. W., Veitch, D. P., Aisen, P. S. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Morris, J. C., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.10.006 · Cited by 523
Self-citationVeitch, D. P., Weiner, M. W., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Morris, J. C., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.08.005 · Cited by 454
Self-citationCommon polygenic variation enhances risk prediction for Alzheimer’s disease
Escott-Price, V., Sims, R., Bannister, C., Harold, D., Vronskaya, M., Majounie, E., Badarinarayan, N., GERAD/PERADES, consortia, I., Morgan, K., et al. (2015) · Brain · doi:10.1093/brain/awv268 · Cited by 414
Longitudinal ComBat: A method for harmonizing longitudinal multi-scanner imaging data
Beer, J. C., Tustison, N. J., Cook, P. A., Davatzikos, C. A., Sheline, Y. I., Shinohara, R. T., & Linn, K. A. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117129 · Cited by 328
NPTX2 and cognitive dysfunction in Alzheimer’s Disease
Xiao, M.-F., Xu, D., Craig, M. T., Pelkey, K. A., Chien, C.-C., Shi, Y., Zhang, J., Resnick, S., Pletnikova, O., Salmon, D., et al. (2017) · eLife · doi:10.7554/elife.23798 · Cited by 316
Weiner, M. W., Veitch, D. P., Aisen, P. S. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Morris, J. C., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.11.007 · Cited by 325
Self-citationLewczuk, P., Riederer, P. F., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramírez, A., Parnetti, L., et al. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 318
Self-citationLi, H., Habes, M., Wolk, D. A., Yong Fan, A., & Initiative, A. D. N. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.02.007 · Cited by 273
Self-citationImpact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014
Weiner, M. W., Veitch, D. P., Aisen, P. S. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J. M., Donohue, M., Green, R. C., Harvey, D. J., Jack, C. R., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.04.005 · Cited by 249
Self-citationBiomarkers for the Early Detection and Progression of Alzheimer's Disease
Counts, S. E., Ikonomovic, M. D., Mercado, N., Vega, I. E., & Mufson, E. J. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0481-z · Cited by 224
Goetzl, E. J., Abner, E. L., Jicha, G. A., Kapogiannis, D., & Schwartz, J. B. (2018) · The FASEB Journal · doi:10.1096/fj.201700731r · Cited by 219
Sheinerman, K. S., Toledo, J. B., Tsivinsky, V. G., Irwin, D., Grossman, M., Weintraub, D., Hurtig, H. I., Chen-Plotkin, A., Wolk, D. A., McCluskey, L. F., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0316-0 · Cited by 154
Self-citationAlzheimer disease brain atrophy subtypes are associated with cognition and rate of decline
Risacher, S. L., Anderson, W. H., Charil, A., Castelluccio, P. F., Shcherbinin, S., Saykin, A. J., Schwarz, A. J., Initiative, F. T. A. D. N., Initiative, A. D. N., Weiner, M. W., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004670 · Cited by 163
Self-citationStern, R. A., Tripodis, Y., Baugh, C. M., Fritts, N. G., Martin, B. M., Chaisson, C., Cantu, R. C., Joyce, J. A., Shah, S., Ikezu, T., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-151028 · Cited by 155
PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases
Cai, Z., Li, S., Matuskey, D., Nabulsi, N., & Huang, Y. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2018.07.038 · Cited by 131
Feature-ranking-based Alzheimer’s disease classification from structural MRI
Beheshti, I., & Demirel, H. (2015) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2015.11.009 · Cited by 129
Molecular and cellular pathophysiology of preclinical Alzheimer’s disease
Mufson, E. J., Ikonomović, M. D., Counts, S., Perez, S. E., Malek‐Ahmadi, M. H., Scheff, S. W., & Ginsberg, S. D. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.05.030 · Cited by 134
Mattsson, N., Lönneborg, A., Boccardi, M., Blennow, K., & Hansson, O. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.02.034 · Cited by 136
Genetic architecture of Alzheimer's disease
Neuner, S. M., TCW, J., & Goate, A. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104976 · Cited by 126
Amyloid Beta and Tau as Alzheimer’s Disease Blood Biomarkers: Promise From New Technologies
Lue, L., Guerra, A., & Walker, D. G. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0074-8 · Cited by 116
Veitch, D. P., Weiner, M. W., Miller, M., Aisen, P. S., Ashford, M. A., Beckett, L. A., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13449 · Cited by 113
Self-citationTrumble, B. C., Stieglitz, J., Blackwell, A. D., Allayee, H., Beheim, B., Finch, C. E., Gurven, M., & Kaplan, H. (2017) · The FASEB Journal · doi:10.1096/fj.201601084r · Cited by 106
Tosun, D., Landau, S. M., Aisen, P. S. S., Petersen, R. C., Mintun, M. A., Jagust, W., Weiner, M. W., & Initiative, A. D. N. (2017) · Brain · doi:10.1093/brain/awx046 · Cited by 110
Self-citationSanches, C., Stengel, C., Godard, J., Mertz, J., Teichmann, M., Migliaccio, R., & Valero‐Cabré, A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.578339 · Cited by 120
Weiner, M. W., Harvey, D. J., Hayes, J., Landau, S. M., Aisen, P. S. S., Petersen, R. C., Tosun, D., Veitch, D. P., Jack, C. R., DeCarli, C. S., et al. (2017) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.02.005 · Cited by 106
Self-citationGupta, Y., Lee, K. H., Choi, K. Y., Lee, J. J., Kim, B. C., Kwon, G., & Initiative, A. D. N. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222446 · Cited by 107
Self-citationPlasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts
Lue, L.-F., Sabbagh, M. N., Chiu, M.-J., Jing, N., Snyder, N. L., Schmitz, C., Guerra, A., Belden, C. M., Chen, T.-F., Yang, C.-C., et al. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00226 · Cited by 105
The cellular model for Alzheimer's disease research: PC12 cells
Xie, D., Deng, T., Zhai, Z., Sun, T., & Xu, Y. D. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1016559 · Cited by 107
Park, M., & Moon, W. (2016) · Korean Journal of Radiology · doi:10.3348/kjr.2016.17.6.827 · Cited by 104
Alosco, M. L., Tripodis, Y., Jarnagin, J., Baugh, C. M., Martin, B. M., Chaisson, C. E., Estochen, N., Song, L., Cantu, R. C., Jeromin, A., et al. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.11.003 · Cited by 109
The price of progress: Funding and financing Alzheimer's disease drug development
Cummings, J. L., Reiber, C. L., & Kumar, P. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.04.008 · Cited by 97
Biomarkers in Neurodegenerative Diseases
Jeromin, A., & Bowser, R. (2017) · Advances in Neurobiology · doi:10.1007/978-3-319-57193-5_20 · Cited by 92
Molecular and Imaging Biomarkers in Alzheimer’s Disease: A Focus on Recent Insights
Villa, C., Lavitrano, M., Salvatore, E., & Combi, R. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030061 · Cited by 94
Alladi, S., & Hachinski, V. (2018) · Neurology · doi:10.1212/wnl.0000000000005941 · Cited by 95
Introduction to special issue: Overview of Alzheimer's Disease Neuroimaging Initiative
Weiner, M. W., & Veitch, D. P. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.05.007 · Cited by 85
Self-citationSørensen, L., & Nielsen, M. (2018) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2018.01.003 · Cited by 86
Akter, A., Sobuj, M. K. A., Islam, M. S., Chakroborty, K., Tasnim, N., Ayon, M. H., Hossain, M. F., & Rafiquzzaman, S. M. (2024) · Future Foods · doi:10.1016/j.fufo.2024.100440 · Cited by 85
Integrating imaging and omics data: A review
Antonelli, L., Guarracino, M. R., Maddalena, L., & Sangiovanni, M. (2019) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2019.04.032 · Cited by 87
Structural MRI-based detection of Alzheimer's disease using feature ranking and classification error
Beheshti, I., Demirel, H., Farokhian, F., Yang, C., & Matsuda, H. (2016) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2016.09.019 · Cited by 80
Alosco, M. L., Sugarman, M. A., Besser, L. M., Tripodis, Y., Martin, B. M., Palmisano, J. N., Kowall, N. W., Au, R., Mez, J., DeCarli, C. S., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180017 · Cited by 76
Huang, J.-L., Qin, M.-C., Zhou, Y., Xu, Z., Yang, S., Zhang, F., Zhong, J., Liang, M.-K., Chen, B., Zhang, W., et al. (2018) · Aging · doi:10.18632/aging.101387 · Cited by 78
Xu, Q., Guo, L., Cheng, J., Wang, M., Geng, Z., Zhu, W., Zhang, B., Liao, W., Qiu, S., Zhang, H., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0627-6 · Cited by 77
Modelling prognostic trajectories of cognitive decline due to Alzheimer's disease
Giorgio, J., Landau, S. M., Jagust, W. J., Peter Tiňo, B., & Kourtzi, Z. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102199 · Cited by 79
Self-citationClassifying Alzheimer's disease with brain imaging and genetic data using a neural network framework
Ning, K., Chen, B., Sun, F., Hobel, Z. B., Zhao, L., Matloff, W. J., & Toga, A. W. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.04.009 · Cited by 79
Self-citationFrölich, L., Peters, O., Lewczuk, P., Gruber, O., Teipel, S. J., Gertz, H., Jahn, H., Jessen, F., Kurz, A., Luckhaus, C., et al. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0301-7 · Cited by 82
Association of Plasma Neurofilament Light With Small Vessel Disease Burden in Nondemented Elderly
Qu, Y., Tan, C., Shen, X., Li, H., Cui, M., Tan, L., Dong, Q., Yu, J., & Initiative, O. B. O. T. A. D. N. (2021) · Stroke · doi:10.1161/strokeaha.120.030302 · Cited by 75
A multi-modal, multi-atlas-based approach for Alzheimer detection via machine learning
Asim, Y., Raza, B., Malik, A. K., Rathore, S., Hussain, L., & Iftikhar, M. A. (2018) · International Journal of Imaging Systems and Technology · doi:10.1002/ima.22263 · Cited by 74
Koike, S., Tanaka, S., Okada, T., Aso, T., Yamashita, A., Yamashita, O., Asano, M., Maikusa, N., Morita, K., Okada, N., et al. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102600 · Cited by 65
Less head motion during MRI under task than resting-state conditions
Huijbers, W., Dijk, K. R. A. V., Boenniger, M. M., Stirnberg, R., & Breteler, M. M. B. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2016.12.002 · Cited by 66
Cochran, J. N., Geier, E. G., Bonham, L. W., Newberry, J. S., Amaral, M. D., Thompson, M. L., Lasseigne, B. N., Karydas, A. M., Roberson, E. D., Cooper, G. M., et al. (2020) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2020.03.010 · Cited by 72
Dallaire‐Théroux, C., Callahan, B. L., Potvin, O., Saïkali, S., & Duchesne, S. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161028 · Cited by 71
Yao, D., Calhoun, V. D., Fu, Z., Du, Y., & Jing Sui （Beijing Normal University）， my correct affiliation is beijing normal university, N. Q. U. O. S. A. T. (2018) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2018.03.008 · Cited by 69
Barupal, D. K., Fan, S., Wancewicz, B., Cajka, T., Sa, M., Showalter, M. R., Baillie, R., Tenenbaum, J. D., Louie, G., Initiative, A. D. N., et al. (2018) · Scientific Data · doi:10.1038/sdata.2018.263 · Cited by 65
Self-citationThe Worldwide Alzheimer's Disease Neuroimaging Initiative: An update
Hendrix, J. A., Finger, B., Weiner, M. W., Frisoni, G. B., Iwatsubo, T., Rowe, C. C., Kim, S. Y., Guinjoan, S. M., Sevlever, G. E., & Carrillo, M. C. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.05.008 · Cited by 65
Self-citationGoukasian, N., Hwang, K. S., Romero, T., Grotts, J., Do, T. M., Groh, J. R., Bateman, D. R., & Apostolova, L. G. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-031947 · Cited by 64
Development of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers
Mankhong, S., Kim, S., Lee, S., Kwak, H., Park, D., Joa, K., & Kang, J. (2022) · Biomedicines · doi:10.3390/biomedicines10040850 · Cited by 72
Tan, L., Wang, H.-F., Tan, M., Tan, C., Zhu, X., Miao, D., Yu, W.-J., Jiang, T., Tan, L., Yu, J., et al. (2016) · Scientific Reports · doi:10.1038/srep26027 · Cited by 66
Self-citationTauopathy in veterans with long-term posttraumatic stress disorder and traumatic brain injury
Mohamed, A. Z., Cumming, P. D., Götz, J., & Nasrallah, F. A. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4241-7 · Cited by 68
Cao, Y., Zhao, L.-W., Chen, Z.-X., & Li, S.-H. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1430465 · Cited by 65
Mallik, A. K., Drzezga, A. E., & Minoshima, S. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.005 · Cited by 64
Hoeijmakers, L., Lesuis, S. L., Krugers, H. J., Lucassen, P. J., & Kőrösi, A. (2018) · Neurobiology of Stress · doi:10.1016/j.ynstr.2018.02.003 · Cited by 66
Nozadi, S. H., Kadoury, S., & Initiative, T. A. D. N. (2018) · International Journal of Biomedical Imaging · doi:10.1155/2018/1247430 · Cited by 57
Liao, J., He, W., Li, L., Wang, J., Gong, L., Zhang, Q., & Lin, Z. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100016 · Cited by 63
Shen, X., Li, J., Wang, H., Li, H., Huang, Y., Yang, Y., Tan, L., Dong, Q., Yu, J., & Initiative, A. D. N. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12104 · Cited by 57
Self-citationAlzheimer’s Disease Neuroimaging Initiative
Bernick, C. B. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108975759.041 · Cited by 60
Yan, Z., Liao, H., Chen, H., Deng, S., Jia, Y., Deng, C., Lin, J., Ge, J., & Zhuo, Y. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-22312 · Cited by 55
Garg, N., Choudhry, M. S., & Bodade, R. M. (2022) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2022.109745 · Cited by 61
Li, K., & Luo, S. (2017) · Statistical Methods in Medical Research · doi:10.1177/0962280217722177 · Cited by 53
Decreased retinal thickness in patients with Alzheimer’s disease is correlated with disease severity
Kim, J., & Kang, B.-H. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224180 · Cited by 53
Demographically adjusted CERAD wordlist test norms in a Norwegian sample from 40 to 80 years
Kirsebom, B., Espenes, R., Hessen, E., Waterloo, K. K., Johnsen, S. H., Gundersen, E., Sando, S. B., Grøntvedt, G. R., Reina, S. T., & Fladby, T. (2019) · The Clinical Neuropsychologist · doi:10.1080/13854046.2019.1574902 · Cited by 52
Khan, A., Park, J. S., Kang, M. H., Lee, H. J., Ali, J., Tahir, M., Choe, K., & Kim, M. O. (2023) · Antioxidants · doi:10.3390/antiox12061284 · Cited by 57
Cai, K., Xu, H., Guan, H., Zhu, W., Jiang, J., Cui, Y. J., Zhang, J., Liu, T., & Wen, W. X. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170875 · Cited by 51
Brain glucose metabolism: Role of Wnt signaling in the metabolic impairment in Alzheimer’s disease
Cisternas, P., & Inestrosa, N. C. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.06.004 · Cited by 52
Huang, J.-L., Xu, Z.-H., Yang, S., Yu, C., Zhang, F., Qin, M.-C., Zhou, Y., Zhong, Z.-G., & Wu, D. (2018) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2018.10.010 · Cited by 51
Kuhn, E., Moulinet, I., Perrotin, A., La Joie, R., Landeau, B., Tomadesso, C., Bejanin, A., Sherif, S., De La Sayette, V., Desgranges, B., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0514-z · Cited by 51
Morbelli, S. D., Arbizu, J., Booij, J., Chen, M.-K., Chételat, G., Cross, D. J., Djekidel, M., Drzezga, A. E., Ekmekçioğlu, Ö., Garibotto, V., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3589-9 · Cited by 50
Initiative, A. D. N., Halawa, O. A., Gatchel, J. R., Amariglio, R. E., Rentz, D. M., Sperling, R. A., Johnson, K. A., & Marshall, G. A. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0471-6 · Cited by 50
Self-citationPositive Airway Pressure and Cognitive Disorders in Adults With Obstructive Sleep Apnea
Shieu, M. M., Zaheed, A. B., Shannon, C., Chervin, R. D., Conceicao, A., Paulson, H. L., Braley, T. J., & Dunietz, G. L. (2022) · Neurology · doi:10.1212/wnl.0000000000200383 · Cited by 48
Shen, T., Jiang, J., Lu, J., Wang, M., Zuo, C., Yu, Z., & Yan, Z. (2019) · Molecular Imaging · doi:10.1177/1536012119877285 · Cited by 46
İş, Ö., Wang, X., Reddy, J. S., Min, Y., Yılmaz, E., Bhattarai, P., Patel, T., Bergman, J., Quicksall, Z., Heckman, M. G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48926-6 · Cited by 55
Self-citationTosun, D., Demir, Z., Veitch, D. P., Weintraub, D. A., Aisen, P. S. S., Jack, C. R., Jagust, W., Petersen, R. C., Saykin, A. J., Shaw, L. M. J., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12480 · Cited by 46
Self-citationLi, K., & Luo, S. (2017) · Statistics in Medicine · doi:10.1002/sim.7381 · Cited by 46
Slater, C. L., & Wang, Q. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.397 · Cited by 47
Deák, F., Freeman, W. M., Ungvari, Z. I., Csiszár, A., & Sonntag, W. E. (2015) · The Journals of Gerontology Series A · doi:10.1093/gerona/glv206 · Cited by 45
Toward precision medicine in neurological diseases
Tan, L., Jiang, T., Tan, L., & Yu, J. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.03.26 · Cited by 42
Li, K., & Luo, S. (2019) · Statistics in Medicine · doi:10.1002/sim.8334 · Cited by 44
Quantitative T2 mapping of white matter: applications for ageing and cognitive decline
Knight, M. J., McCann, B., Tsivos, D., Dillon, S., Coulthard, E. J., & Kauppinen, R. A. (2016) · Physics in Medicine and Biology · doi:10.1088/0031-9155/61/15/5587 · Cited by 44
Advances in Studying Brain Morphology: The Benefits of Open-Access Data
Madan, C. R. (2017) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2017.00405 · Cited by 40
Looking for Alzheimer's Disease morphometric signatures using machine learning techniques
Donnelly-Kehoe, P. A., Pascariello, G. O., & Gómez, J. C. (2017) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2017.11.013 · Cited by 41
Open innovation: Towards sharing of data, models and workflows
Conrado, D. J., Karlsson, M. O., Romero, K., Sarr, C., & Wilkins, J. J. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.06.035 · Cited by 41
Stuve, O., Weideman, R. A., McMahan, D. M., Jacob, D. A., & Little, B. B. (2020) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286420935676 · Cited by 40
Xie, L., Das, S. R., Wisse, L. E. M., Ittyerah, R., de Florès, R., Shaw, L. M. J., Yushkevich, P. A., Wolk, D. A., & Initiative, A. D. N. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01210-z · Cited by 50
Self-citationBerlyand, Y., Weintraub, D. A., Xie, S. X., Mellis, I. A., Doshi, J. J., Rick, J. H., McBride, J. D., Davatzikos, C. A., Shaw, L. M. J., Hurtig, H. I., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147319 · Cited by 39
Self-citationMagnetic Resonance Imaging to Detect Early Molecular and Cellular Changes in Alzheimer's Disease
Knight, M. J., McCann, B., Kauppinen, R. A., & Coulthard, E. J. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00139 · Cited by 41
An, L., Adeli, E., Liu, M., Zhang, J., Lee, S., & Shen, D. G. (2017) · Scientific Reports · doi:10.1038/srep45269 · Cited by 40
Wang, Z., Jin, T., Le, Q., Liu, C., Wang, X., Wang, F., & Ma, L. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.10.009 · Cited by 32
Li, Y., Li, Y., & Chen, J. (2021) · Microchemical Journal · doi:10.1016/j.microc.2021.106438 · Cited by 37
Brendel, M., Initiative, A. D. N., Sauerbeck, J., Greven, S., Kotz, S., Scheiwein, F., Blautzik, J., Delker, A., Pogarell, O. M., Ishii, K., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170387 · Cited by 37
Self-citation
Metadata
- Authors
- Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Luthman, J., Morris, J. C., Petersen, R. C., Saykin, A. J., Shaw, L., Shen, L., Schwarz, A., Toga, A. W., Trojanowski, J. Q., & Initiative, A. D. N.
- Affiliations
- San Francisco VA Medical Center (US)
- University of California San Diego (US)
- University of California, Davis (US)
- Washington University in St. Louis (US)
- Biogen (United States) (US)
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- University of California, Berkeley (US)
- Eisai (United States) (US)
- Indiana University Indianapolis (US)
- University of Pennsylvania (US)
- Eli Lilly (United States) (US)
- University of Southern California (US)
- Corresponding author
- Weiner, Michael W.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2015-06
- Volume
- 11
- Issue
- 6
- Pages
- e1-120
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC5469297
- OpenAlex
- W1797408175
- Cited by
- 348
- References
- 565
- Citations by year
- 2026: 27 · 2025: 22 · 2024: 28 · 2023: 18 · 2022: 18 · 2021: 43 · 2020: 28 · 2019: 38 · 2018: 36 · 2017: 45 · 2016: 33 · 2015: 11
- FWCI
- 5.74
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion, other-oa)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- Biogen
- Synarc
- TauRx Pharmaceuticals
- Bayer HealthCare
- Servier
- Ipsen
- National Institutes of Health (5u01ag024904-10)
- National Institute on Aging (U01-AG-024904, P30AG010129, P30AG010133, R01AG012975, R01AG030048, P30AG036468, P30AG010124, P01AG009215, P01AG017586, U01AG010483, U01AG029213, P50AG005681, R01AG016381, P01AG003991, R01AG019771, RC2AG036535, P01AG019724)
- National Cancer Institute (P30CA093373)
- National Institute of General Medical Sciences (R01GM088336)
- National Institute of Neurological Disorders and Stroke (P50NS053488)
- National Center for Research Resources (UL1RR024146, R25RR026008)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, Alzheimer's Disease Neuroimaging Initiative
- MeSH terms
- Alzheimer Disease, Brain, Humans, Radionuclide Imaging, Multicenter Studies as Topic, Biomarkers, Nootropic Agents, Early Diagnosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
